Clinical Trial Update: A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of golimumab (Simponi) in active rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED